Professional Background - Brendan completed a Ph.D. in organic synthesis at Stanford University in 2009 [1] - Worked at Merck, a major pharmaceutical company, from 2009 to 2013 [1] - Gained experience in biotech startups, including Theravance and Aspira, before joining Caltech [1] - Co-founded 1200 Pharma as its first employee, securing significant investment (8 figures) when it spun out of Caltech [1] Investment Focus - Remains an active investor with a focus on market trends, particularly in biotechnology stocks [1] Note: The content does not provide specific company or industry analysis, financial data, or investment opportunities, as it primarily focuses on an individual's professional background and investment interests. The disclosure and risk-related sections have been excluded as per the task instructions.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores ...

Most recently in the ever-growing biotech industry, investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Today, we'll check checking in with three heavy-hitting biotech stocks and how they've been faring on the charts. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stock is finally on the reboun ...

Core Viewpoint - Incyte's recent earnings report showed mixed results, with adjusted earnings missing estimates but total revenues exceeding expectations, driven by strong sales of its lead drug Jakafi and the newly launched Opzelura cream [2][3]. Financial Performance - Adjusted earnings for Q3 2024 were $1.07 per share, missing the Zacks Consensus Estimate of $1.12, and down from $1.10 per share in the same quarter last year [2]. - Total revenues reached $1.14 billion, reflecting a year-over-year growth of 23.8%, surpassing the Zacks Consensus Estimate of $1.09 billion [3]. Product Sales Breakdown - Jakafi generated revenues of $741.2 million, a 16% increase from the previous year, driven by a 10% rise in total demand, and exceeded the Zacks Consensus Estimate of $717.5 million [4]. - Opzelura cream sales amounted to $139.3 million, up 52% year over year, surpassing the Zacks Consensus Estimate of $130.8 million, attributed to growth in new patient starts and refills [5]. - Zynyz, a newly approved drug, generated $0.69 million in sales, while Iclusig and Pemazyre reported revenues of $29.7 million (up 7%) and $20.7 million (down 9%), respectively [6]. Royalty Revenues - Jakavi royalty revenues from Novartis increased by 20% to $115.7 million, beating the Zacks Consensus Estimate of $104.7 million [8]. - Royalty revenues from Tabrecta sales were $5.9 million, up 43% year over year [9]. - Olumiant's product royalty revenues totaled $34.8 million, a 17% increase, but missed the Zacks Consensus Estimate of $35.2 million [10]. Expenses and Guidance - Adjusted R&D expenses rose to $525.3 million, a 51% increase year over year, primarily due to a $100 million milestone payment [11]. - Adjusted selling, general, and administrative expenses were $277.3 million, up 15% from the prior year [12]. - Incyte raised its 2024 revenue guidance for Jakafi to a range of $2.74-$2.77 billion, and adjusted R&D expenses are now expected to be between $2.395-$2.435 billion [13]. Recent Developments - In August 2024, Incyte and Syndax Pharmaceuticals received FDA approval for axatilimab-csfr, branded as Niktimvo, for chronic graft-versus-host disease [14]. Market Position and Outlook - Incyte's stock has seen a downward trend in estimates, with a consensus estimate shift of -6.38% [15][16]. - The company holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [18]. - Incyte operates within the Zacks Medical - Biomedical and Genetics industry, where competitor Alkermes has shown an 11.4% gain over the past month [19].

Incyte (INCY) suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).Consequently, shares of Incyte were down 9% on Nov. 18 in after-market trading.Shares of Incyte have risen 5.4% year to date against the industry’s 11.1% decline.Image Source: Zacks Investment ResearchINCY Pauses Enrollment in CSU StudyIncyte announced that it will pause enrollment in the ongoing phase II study of MRGPRX2 in CSU due to certain in vivo preclinical toxicology findings ...

KEY TAKEAWAYSIncyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.Enrollment in the ongoing Phase 2 trial of a drug to treat chronic spontaneous urticaria (CSU), or chronic hives, was paused.The biopharmaceutical firm also said it won't develop the drug to treat cholestatic pruritus (CP), a liver disorder that causes intense itching. Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharm ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been nearly two years since my previous Incyte Corporation (NASDAQ: INCY ) article, where I discussed the potential for the company to maintain their growth trajectory despite the threat of Jakafi's impending patent expiration. Looking back, it lo ...

On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion. Jakafi (ruxolitinib) net product revenues increased to $741.18 million, up 16% year over year, primarily due to a 10% increase in total demand. Guidance: Incyte forecasts 2024 Jakafi revenue of $2.74 billion—$2.77 billion, up from prior guidance of $2.71 billion—$2.75 billion. BofA Securities analyst upgraded Incyte's stock, citing strong demand for Jakafi liſts ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3136539 (Stat ...

Incyte Corporation (NASDAQ:INCY) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Barry Flannelly - General Manager, North America Conference Call Participants Mic ...